Ira Shoulson

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Ira Shoulson
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 51:604-12. 2002
  2. pmc Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS
    Annie Killoran
    University of Rochester, Rochester, NY, USA
    Neurology 80:2022-7. 2013
  3. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
  4. ncbi request reprint Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
  5. ncbi request reprint A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
  6. ncbi request reprint The relationship between CAG repeat length and clinical progression in Huntington's disease
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 23:1223-7. 2008
  7. pmc Fatigue in levodopa-naive subjects with Parkinson disease
    G Schifitto
    University of Rochester, NY, USA
    Neurology 71:481-5. 2008
  8. ncbi request reprint Depressed mood and suicidality in individuals exposed to tetrabenazine in a large huntington disease observational study
    E Ray Dorsey
    Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY, USA
    J Huntingtons Dis 2:509-15. 2013
  9. pmc Altered cholesterol and fatty acid metabolism in Huntington disease
    Robert C Block
    Division of Epidemiology, Department of Community and Preventive Medicine and Preventive Cardiology Unit, Box 644, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14620, USA
    J Clin Lipidol 4:17-23. 2010
  10. pmc Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study
    Kevin M Biglan
    University of Rochester, Rochester, New York, USA
    Mov Disord 24:1763-72. 2009

Detail Information

Publications30

  1. ncbi request reprint Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Ira Shoulson
    University of Rochester Medical Center, Rochester, NY 14620, USA
    Ann Neurol 51:604-12. 2002
    ....
  2. pmc Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS
    Annie Killoran
    University of Rochester, Rochester, NY, USA
    Neurology 80:2022-7. 2013
    ..We aimed to describe the clinical phenotype conferred by the intermediate-length huntingtin allele CAG repeat expansion in a population-based study...
  3. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  4. ncbi request reprint Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  5. ncbi request reprint A longitudinal program for biomarker development in Parkinson's disease: a feasibility study
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 24:2081-90. 2009
    ..The PostCEPT cohort and associated studies strongly support the feasibility of the LABS-PD approach of retaining and repurposing clinical trial cohorts to collect longitudinal clinical and biomarker data...
  6. ncbi request reprint The relationship between CAG repeat length and clinical progression in Huntington's disease
    Bernard Ravina
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Mov Disord 23:1223-7. 2008
    ..This finding may account for the variable results from previous studies examining CAGn and progression. Adjusting for CAGn may be important for clinical trials...
  7. pmc Fatigue in levodopa-naive subjects with Parkinson disease
    G Schifitto
    University of Rochester, NY, USA
    Neurology 71:481-5. 2008
    ..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial...
  8. ncbi request reprint Depressed mood and suicidality in individuals exposed to tetrabenazine in a large huntington disease observational study
    E Ray Dorsey
    Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY, USA
    J Huntingtons Dis 2:509-15. 2013
    ..Tetrabenazine, a treatment for chorea in Huntington disease, carries a boxed warning due to safety, especially related to suicidality...
  9. pmc Altered cholesterol and fatty acid metabolism in Huntington disease
    Robert C Block
    Division of Epidemiology, Department of Community and Preventive Medicine and Preventive Cardiology Unit, Box 644, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14620, USA
    J Clin Lipidol 4:17-23. 2010
    ..Drugs that combat the dysregulated lipid milieu in Huntington disease may help treat this perplexing and catastrophic genetic disease...
  10. pmc Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study
    Kevin M Biglan
    University of Rochester, Rochester, New York, USA
    Mov Disord 24:1763-72. 2009
    ..Longitudinal assessment will help inform whether motor items will be useful measures in preventive clinical trials...
  11. pmc Therapeutic directions for Parkinson's disease
    Ira Shoulson
    Department of Neurology, University of Rochester, Rochester, New York 14620, USA
    Mov Disord 25:S152-4. 2010
    ..These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples...
  12. ncbi request reprint Communicating clinical trial results to research participants
    E Ray Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 223, Rochester, NY 14620, USA
    Arch Neurol 65:1590-5. 2008
    ..Communicating clinical trial results to research participants is seldom accomplished in a timely or an effective manner...
  13. ncbi request reprint Sociology of collaborative research groups
    Ira Shoulson
    University of Rochester School of Medicine and Dentistry, NY 14620, USA
    Amyotroph Lateral Scler Other Motor Neuron Disord 5:118-20. 2004
  14. ncbi request reprint Rasagiline improves quality of life in patients with early Parkinson's disease
    Kevin M Biglan
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Mov Disord 21:616-23. 2006
    ..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline...
  15. ncbi request reprint Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline
    Clifford W Shults
    Department of Neurosciences, Mail Code 0662, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0662, USA
    Arch Neurol 59:1541-50. 2002
    ..Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression...
  16. ncbi request reprint Measuring the effects of therapy in Parkinson disease
    Clifford W Shults
    JAMA 291:2430-1; author reply 2431. 2004
  17. ncbi request reprint Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
    Hypertension 52:587-93. 2008
    ..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet...
  18. ncbi request reprint A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations
    Karen Blindauer
    Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
    Arch Neurol 63:210-6. 2006
    ..Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration...
  19. ncbi request reprint Levodopa and the progression of Parkinson's disease
    Stanley Fahn
    Columbia University, New York, USA
    N Engl J Med 351:2498-508. 2004
    ..This study assessed the effect of levodopa on the rate of progression of Parkinson's disease...
  20. ncbi request reprint Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 23:653-9; quiz 776. 2008
    ..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
  21. ncbi request reprint Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments
    Nicholas H G Holford
    Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
    J Pharmacokinet Pharmacodyn 33:281-311. 2006
    ..We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression...
  22. ncbi request reprint Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    J Antonelle deMarcaida
    Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
    Mov Disord 21:1716-21. 2006
    ..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
  23. doi request reprint A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
    Samuel Frank
    Department of Neurology, Boston University School of Medicine, Boston, MA, USA
    Clin Neuropharmacol 31:127-33. 2008
    ..To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal...
  24. ncbi request reprint Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial
    Andrew Siderowf
    Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 17:758-63. 2002
    ..The findings are in agreement with previous reports on interrater reliability...
  25. ncbi request reprint Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies
    James Swanson
    University of California, Irvine, Department of Pediatrics, Child Development Center, CA, USA
    Arch Gen Psychiatry 60:204-11. 2003
    ..Tachyphylaxis was hypothesized to account for the reduced effects, and an ascending drug delivery pattern was proposed to overcome this acute tolerance...
  26. pmc Verbal episodic memory declines prior to diagnosis in Huntington's disease
    Andrea C Solomon
    Department of Psychological and Brain Sciences, Indiana University, 1101 E 10th Street, Bloomington, IN 47405, USA
    Neuropsychologia 45:1767-76. 2007
    ..These findings indicate that verbal episodic memory is affected in early pre-diagnostic HD and may decline as striatal volumes decrease and individuals approach the motor diagnostic threshold...
  27. pmc Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  28. ncbi request reprint Interrater agreement in the assessment of motor manifestations of Huntington's disease
    Penelope Hogarth
    Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Mov Disord 20:293-7. 2005
    ..We expect these findings to translate to a similar level of interobserver agreement in the clinical trial setting involving experienced investigators examining live patients...
  29. ncbi request reprint Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 23:690-9. 2008
    ..Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials...